Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astex Pharmaceuticals, Inc., Celgene Corporation, and Takeda Oncology.

Community Practice Connections™: A New Wave of Progress in Myelodysplastic Syndromes: Optimizing Outcomes from Diagnosis to Treatment

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Internet - based

Activity Overview

A rapidly evolving treatment landscape and changes to prognostic scoring systems have created a practice gap for healthcare providers treating patients with myelodysplastic syndromes (MDSs). This online enduring activity will address challenges that clinicians face during the diagnostic process and accurate confirmation of MDS versus other causes of anemia. Case-based questions are incorporated into this program for participants to virtually apply the presented concepts, followed by videos of interviews with top experts in which they discuss the rationale behind the best answer option for each question. In addition, prominent experts discuss the latest data for management of high-risk and low-risk MDS for patients who are eligible for transplant and for those who are not, including treatment of MDS in older adults. Experts will discuss the implications for clinical practice as well as their own preferences and perspectives on clinical trial data in relation to daily practice.

This Community Practice Connection™ program will help clinicians meet the challenge of acquiring this knowledge through a series of video interviews with top experts in MDS on making an accurate diagnosis of MDS, best practices in risk stratification of patients with MDS, and overcoming commonly observed clinical challenges, as well as reviewing novel therapeutic options for differing levels of risk and patient characteristics.

Benefits of Participating

  • Increase knowledge and competence regarding diagnostic and prognostic assessment of MDS
  • Learn strategies to effectively manage complex cases of low-risk and high-risk MDS within the context of best practices from leading experts in MDS
  • Utilize real-world case examples provided by experts to support effective clinical decision making in your practice
  • Build confidence in your knowledge of how to optimally treat older adults with MDS via incorporation of novel therapeutic strategies and agents into treatment planning
  • Improve knowledge of best practice management of patients after treatment failure

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astex Pharmaceuticals, Inc., Celgene Corporation, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with myelodysplastic syndromes. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of MDS will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review tools for MDS classification and risk stratification, based on morphological, clinical, and cytogenetic criteria
  • Evaluate strategies for tailoring therapy for patients with MDS based on risk stratification and patient comorbidities in the frontline setting and beyond
  • Translate clinical trial evidence into real-world practice for the management of MDS
  • Assess data from recent clinical trials evaluating efficacy and safety of novel therapies and strategies for the treatment of patients with MDS

Faculty, Staff, and Planners’ Disclosures


Guillermo Garcia-Manero
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Amphivena, Helsinn, Novartis, AbbVie, Celgene, Astex, Onconova, H3 Biomedicine, Merck; Consultant: Celgene, Astex, Amphivena.

Michael R. Savona
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Director, Hematologic Malignancies Research and Early Therapy Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant Research Support: Takeda, TG Therapeutics, Incyte, Astex; Consultant: Astex, AbbVie, Celgene, Karyopharm, Selvitz; Shareholder: Karyopharm.

Jamile M. Shammo
Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director, Hematology/Oncology Fellowship Program
Section of Hematology and Stem Cell Transplantation
Rush University Medical Center
Chicago, IL

Disclosures: Grant Research Support: Celgene, Astex, Onconova, Alexion, CTI BioPharma; Consultant: Celgene, Incyte, Alexion, Astex, Sanofi Genzyme, Novartis; Speakers Bureau: Celgene, Incyte, Alexion, Sanofi Genzyme; Shareholder: AbbVie.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician of diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By